Comparison of ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR/DTR Pseudomonas aeruginosa infections: a systematic review and meta-analysis - PubMed
5 hours ago
- #ceftazidime-avibactam
- #ceftolozane-tazobactam
- #MDR/DTR Pseudomonas aeruginosa
- Ceftolozane-tazobactam and ceftazidime-avibactam are first-line treatments for MDR/DTR Pseudomonas aeruginosa infections.
- A systematic review and meta-analysis compared the two drugs, analyzing clinical cure, resistance development, microbiological failure, and mortality rates.
- Ceftolozane-tazobactam showed a higher clinical cure rate compared to ceftazidime-avibactam (OR 1.82; 95% CI 1.10-2.99).
- No significant differences were found in microbiological failure, 90-day resistance development, or 30-day mortality rates between the two treatments.
- The study included six observational studies with a total of 1,161 patients (644 on ceftolozane-tazobactam and 517 on ceftazidime-avibactam).
- The findings suggest ceftolozane-tazobactam may be more effective for clinical cure in MDR/DTR PA infections after adjusting for confounders.